



Press Release no.1
NSE completes its 1700th Normal Settlement

The Exchange has successfully completed its 1700th Normal Settlements (Rolling T+2 following SEBI directive) since inception i.e., Settlement Number N – 2006225 on November 29, 2006. The settlement statistics are as follows:

Particulars	Values
	N – 2006225
Total traded quantity (lakhs)	2835.24
Total traded value (Rs. In Crores)	7091.68
Total value of the settlement (Securities) (Rs. In Crores)	1903.55
Total value of the settlement (Funds) (Rs. In Crores)	1205.4
Shortages for the settlement	0.57%
% of Delivery (No. of shares deliverable / No. of shares traded)	29.90%

Retail Debt Market has completed its 974th settlement details of which are as follows:

Settlement No.	Traded Value	Settlement Value	
		Securities	Funds
D- 2006225	NIL	NIL	NIL

Press Release no.2
News about Opto Circuits (India) Limited

The media had reports that Opto Circuits (India) Limited is close to announcing an overseas acquisition.

The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company.

Opto Circuits (India) Limited has vide its letter inter-alia stated, "We would like to clarify that as a part of its business strategy, Opto Circuits (I) Ltd. is on a constant lookout for acquisitions and during this process, the company has approached a number of companies here and abroad. However, the company is yet to finalize any such deal. The aforesaid news mentioned in the media has not been provided by the Company and the Company denies such developments at the moment. We will inform the Stock Exchanges about any such development."

Press Release no.3
News about Bal Pharma Limited

The media had reports that the promoters of Bal Pharma Limited are in discussions to offload stake to a strategic partner.

The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company.

Bal Pharma Limited has vide its letter inter-alia stated, "We deny the cited news in toto and in particular that the promoters of the Company are in discussion to offload stake to strategic partners."